Member Info for Mulder

Should never have dropped to 90p Buyers have returned en-masse as shown by the RSI which has doubled in days from 20 to 41.

RSI has steadily climbed from 10 to 20 past few days. Still heavily oversold technically.

11-Sep-17 Canaccord Genuity Buy 2,350.00 2,080.00 Reiteration

I hope to see several Director buys in the coming days. That was a good bounce off 1450p Technically this is still very oversold. JP Morgan are shorting this so not surprised to see them downgrade it today. They are the only fund shorting it. Not a big short 0.6% which hopefully has been reduced

After the unwarranted 15% fall this alone yields 4.6%

I think the market is both over-reacting to the issue of the generic Advair approval and under-appreciating the strength of Vectura’s overall business and growth prospects, post-merger. The City’s downgraded underlying earnings-per-share (EPS) consensus for the current year of 3.5p gives a price-to-earnings (P/E) ratio of 28. This falls to below 20 next year on forecasts of 43% EPS growth to 5p. The price-to-earnings growth (PEG) ratio is less than 0.5, which is deeply on the value side of the PEG fair-value marker of one, and leads me to conclude that now could be a great time to buy a slice of this business. http://www.fool.co.uk/investing/2017/09/06/there-could-be-hidden-value-in-these-ftse-250-stocks/

07-Sep-17 Buy Trade Notifier Information for Vectura Group Andrew Derodra 89.7 GBX 82,000 415142 07-Sep-17 Buy Trade Notifier Information for Vectura Group James Ward-Lilley 90.45 GBX 82,918 461860 RSI has jumped from 20 to 33 indicating buyers have returned but this still remains in oversold territory. Once we get rid of the day traders we should see this run up back to the 108-110p range. I would think predators have noticed this is now trading around book value and may make an offer. As The Motley Fool pointed out yesterday it is trading at a deep discount. Market cap at the time of the merger was £1Bn combined. Market cap now is just £551M Anyone looking to obtain a high quality respiratory portfolio could buy Vectura on the cheap after this fall. ******************************************************************* Shares of FTSE 250 pharma firm Vectura (LSE: VEC) dived 14% to a new 52-week low of 94p in early trading this morning. This despite it releasing first-half results “in line with board expectations for the full year” and stressing its “multiple opportunities to create substantial shareholder value” for the remainder of the year and beyond. Excellent progress Vectura posted a 6.6% rise in H1 revenue, with recurring revenue increasing 26.1%. However, losses widened, although this was mainly due to amortisation of the intangible assets recognised on its merger with Skyepharma last year. If we look back to that deal, we can get an idea of how much value may be hidden in the combined group. On 15 March 2016, the day before the announcement of the all-share merger, Vectura’s shares closed at 146.6p, giving it a market capitalisation of £602m. Skyepharma’s market cap was £412m, making the aggregate of the two companies £1,014m. Today, the market is valuing the combined group at just £665m. Vectura reported “excellent progress” with the merger integration in this morning’s results. It said it remains on track to deliver its original £10m target annual cost synergies by 2018 and has identified further synergies of £1m to £2m from 2018. Over-reaction and under-appreciation The reason behind Vectura’s current depressed valuation is downgraded analysts’ earnings forecasts. These were the result of an announcement in May of a delay in approval from the US Food and Drug Administration for a partner’s generic version of GlaxoSmithKline‘s asthma medication Advair Diskus. While Vectura and its partner are confident of receiving approval in due course, it no longer anticipates receiving an approval milestone payment or sales royalties this year. I think the market is both over-reacting to the issue of the generic Advair approval and under-appreciating the strength of Vectura’s overall business and growth prospects, post-merger. The City’s downgraded underlying earnings-per-share (EP

Seems like buyers returned at 1445p Savagery and butchery by the MM's and shorters. Totally obscene drop on rising revenues and a 5% fall in profits. This was 2600p not so long ago.

Good to see the CEO buying here also. No one knows the company better than him. I hear they are as puzzled by the 20% fall in 2 days as the rest of us. Totally unwarranted drop. Savagery and butchery by MM's again I'm afraid. Looking at a run back up to 110p near term.

No this is nothing like Carillion which is in the troubled construction sector & where the short sellers IMO had inside information about the £850M black hole that was finally revealed and left the company in negative equity+ with further contract losses. Shorts there were 23%; here 0.6% currently. Shareholder equity is actually up here, debt is within target and no one can deny a P/E of 7.5 is ultra-cheap. Moronic price drop caused by manipulators? Agree yet the FCA's market abuse and intelligence teams seemingly do nothing even when spoonfed information and when tipped off as they have been again today.

I can sense your frustration and anger here. However I do think this is oversold . Even from a technical perspective an RSI of 20 is very low. As stated yesterday the balance sheet remains incredibly strong, revenue is growing and it is trading below book value now. Director also bought today which could be a sign of a bottom.

A brutal day today and went from 1580p to 1550p just in the closing auction! This is a relatively defensive business though with a P/E below 8 and dividend of 6.6%. We are at 4-5 year lows. Unfairly savaged IMO

2 high-yield stocks you might want to buy right now While Go-Ahead still clearly faces some colossal obstacles at home, glass-half-full investors will point to the London company’s ambitious international expansion strategy as reason to expect meaty returns in the years ahead. Indeed, Go-Ahead advised today that it is “progressing towards a new target for international operations to contribute 15% to 20% of group profit within five years.” The company signed bus contracts in Singapore and Ireland, and rail contracts in Germany, in the last year and is exploring transport contracts in Scandinavia and Australia at the moment. And in the meantime the business is expected to continue doling out chunky dividends. The travel titan forked out a full-year payment of 102.1p per share in fiscal 2017 — a figure which trumped City estimates of a 100.2p reward — and is currently predicted to lift this to 103.2p in the present period. As a result, Go-Ahead offers a gargantuan 6.5% yield. And while earnings are expected to tip 4% lower this year, the dividend is still covered a healthy 1.9 times, roughly in line with the widely-considered security watermark of two times. http://www.fool.co.uk/investing/2017/09/07/2-high-yield-stocks-you-might-want-to-buy-right-now/

.

Go-Ahead Group (The) PLC GOG Liberum Capital Buy 1,657.00 1,753.00 1,910.00 1,910.00 Reiterates

Yes as I said strip the £53M out and the underlying business made a profit. Also the balance sheet, cash balance and equity ratio >5 is very solid here. *Vulnerable to a take over at these prices IMO and the buyer will barely be paying above book value so great value.

RSI is rising - decent number of buys coming in.

Vectura Group PLC VEC Peel Hunt Hold 92.23 95.00 160.00 160.00 Reiterates

06-Sep-17 Buy Trade Notifier Information for Dixons ****hone Katie Bickerstaffe 165 GBX 10,000 369568 25-Aug-17 Buy Trade Notifier Information for Dixons ****hone Tony DeNunzio 178 GBX 50,000 100000 25-Aug-17 Buy Trade Notifier Information for Dixons ****hone Andrea Gisle Joosen 178 GBX 2,600 11676 25-Aug-17 Buy Trade Notifier Information for Dixons ****hone Sebastian James 178 GBX 25,000 631835 25-Aug-17 Buy Trade Notifier Information for Dixons ****hone Humphrey Singer 178 GBX 25,000 444748 24-Aug-17 Buy Trade Notifier Information for Dixons ****hone Lord Livingston 182 GBX 54,655 105631 24-Aug-17 Buy Trade Notifier Information for Dixons ****hone Fiona McBain 182 GBX 19,129 19129

Assets £800M Liabilities £148M Net assets/equity £652M Equity ratio = 5.40 That is very strong. Other positives Recurring revenue £71M H1 2017 Vs £56M H1 2016 +27% Device sales up £39.4M H1 2017 Vs £23.6M H1 2016 +67%